To examine the frequency, onset, and duration of the treatment-emergent adverse events (TEAEs) in MOXIe Part 2 that occurred more often in patients with Friedreich ataxia treated with omaveloxolone as compared to those treated with placebo.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: